Friday 6 November 2026
Export CHE’s income statement to Excel — free account
Chemed Corporation
CHE Healthcare Medical Care Facilities
Chemed Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 4.06% from fiscal 2024.
- Revenue
- +10.6%
- EPS
- +23.1%
- Free cash flow
- −45.3%
Quarter to September 2026, against a year earlier
533.55
15.09
−2.75%
Follow CHE
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
24.10 | 23.37 | 20.54 | 23.19 |
+8 more quarters Free account |
P/S ratio |
2.48 | 2.36 | 2.03 | 2.43 | |
P/FCF ratio |
22.22 | 18.70 | 13.53 | 18.67 | |
P/Operating CF |
116.54 | 72.34 | 58.55 | 46.13 | |
P/B ratio |
7.66 | 7.39 | 6.09 | 6.29 | |
Price to Tangible BV |
236.62 | 116.84 | 64.51 | 26.83 | |
EV/Sales |
2.55 | 2.40 | 2.06 | 2.45 | |
EV/EBITDA |
15.47 | 15.00 | 13.31 | 15.34 | |
EV/Operating CF |
18.69 | 16.00 | 11.82 | 15.94 | |
EV/FCF |
22.87 | 19.02 | 13.74 | 18.75 | |
Quick Ratio |
0.92 | 0.72 | 0.72 | 0.90 | |
Current Ratio |
1.11 | 0.91 | 0.85 | 1.05 | |
Net Debt/EBITDA |
1.65 | 0.94 | 0.73 | (0.64) | |
Debt/Assets |
13.73% | 8.86% | 5.94% | 0.00% | |
Debt/Equity |
0.27 | 0.17 | 0.11 | 0.00 | |
Asset Turnover |
1.59 | 1.57 | 1.56 | 1.58 | |
Operating CF/Net income |
0.79 | 1.25 | 1.33 | 1.74 | |
Capex/Depreciation |
(1.07) | (0.89) | (1.00) | (0.95) | |
Interest Coverage |
45.98 | 49.86 | 165.19 | 193.19 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
16.13% | 17.11% | 17.39% | 16.50% | |
Intangible Assets out of Total Assets |
0.49 | 0.49 | 0.50 | 0.49 | |
Share Based Compensation of Revenue |
1.32% | 1.68% | 1.62% | 1.58% | |
Graham Net Nets |
(0.07) | (0.07) | (0.08) | (0.04) | |
Graham Number |
176.38 | 168.14 | 160.18 | 168.04 | |
Earnings Yield |
4.15% | 4.28% | 4.87% | 4.31% | |
Free Cash Flow Yield |
4.50% | 5.35% | 7.39% | 5.36% | |
Revenue per Share |
52.91 | 51.10 | 48.08 | 44.40 | |
Operating CF per Share |
4.33 | 6.44 | 6.45 | 9.27 | |
Capex per Share |
(1.43) | (1.16) | (1.24) | (1.08) | |
Free Cash Flow per Share |
2.91 | 5.28 | 5.21 | 8.20 | |
Cash per Share |
3.71 | 3.05 | 1.23 | 5.18 | |
Shareholders Equity per Share |
65.97 | 63.04 | 62.01 | 68.02 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
65.97 | 63.04 | 62.01 | 68.02 | |
Free Cash Flow |
37.94 | 69.58 | 71.24 | 118.00 | |
Working Capital |
34.79 | (28.61) | (47.35) | 15.49 | |
Capital Expenditures |
(18.65) | (15.23) | (16.98) | (15.53) | |
Net Current Asset Value |
(491.29) | (457.84) | (413.76) | (256.17) | |
EV/EBIT |
18.30 | 17.87 | 15.99 | 18.30 | |
Capex to Sales |
0.03 | 0.02 | 0.03 | 0.02 | |
Price to Operating Income |
17.78 | 17.57 | 15.75 | 18.21 | |
| Other line items | |||||
Average Receivables |
235.22 | 186.76 | 250.68 | 176.87 | |
Average Payables |
56.70 | 67.79 | 56.70 | 54.30 | |
Average Inventory |
7.99 | 8.39 | 7.50 | 7.87 | |
Average Assets |
1,671.03 | 1,648.72 | 1,631.17 | 1,603.38 | |
Average Common Equity |
969.05 | 1,014.50 | 1,014.88 | 1,049.20 |
Columns are period end dates · fundamentals updated 5 Nov 2026